Which has better valuation and earnings, OGN or XNCR?

Organon & Co. has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organon & Co. $6.16B 0.57 $187M $0.93 14.46 Xencor $125.58M 8.31 -$91.92M -$2.29 N/A

Is OGN or XNCR more profitable?

Organon & Co. has a net margin of 3.99% compared to Xencor's net margin of -177.10%. Organon & Co.'s return on equity of 99.95% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Organon & Co. 3.99% 99.95% 6.22% Xencor -177.10% -28.77% -20.52%

Does the media prefer OGN or XNCR?

In the previous week, Organon & Co. had 2 more articles in the media than Xencor. MarketBeat recorded 6 mentions for Organon & Co. and 4 mentions for Xencor. Xencor's average media sentiment score of 0.65 beat Organon & Co.'s score of 0.32 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNLI or XNCR?

In the previous week, Xencor had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Xencor and 2 mentions for Denali Therapeutics. Xencor's average media sentiment score of 0.65 beat Denali Therapeutics' score of 0.33 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, NAMS or XNCR?

Xencor has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewAmsterdam Pharma $22.50M 163.14 -$203.82M -$1.79 N/A Xencor $125.58M 8.31 -$91.92M -$2.29 N/A

Does the media prefer VKTX or XNCR?

In the previous week, Viking Therapeutics had 3 more articles in the media than Xencor. MarketBeat recorded 7 mentions for Viking Therapeutics and 4 mentions for Xencor. Xencor's average media sentiment score of 0.65 beat Viking Therapeutics' score of 0.25 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, TLX or XNCR?

Telix Pharmaceuticals has higher revenue and earnings than Xencor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.31 -$7.12M N/A N/A Xencor $125.58M 8.31 -$91.92M -$2.29 N/A

Does the media prefer TLX or XNCR?

In the previous week, Telix Pharmaceuticals and Telix Pharmaceuticals both had 4 articles in the media. Xencor's average media sentiment score of 0.65 beat Telix Pharmaceuticals' score of 0.44 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xencor (XNCR) Competitors

$14.08 +0.07 (+0.50%)

As of 04:00 PM Eastern

Compare

XNCR vs. OGN, DNLI, NAMS, VKTX, and TLX

Should you buy Xencor stock or one of its competitors? MarketBeat compares Xencor with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xencor include Organon & Co. (OGN), Denali Therapeutics (DNLI), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry.

How does Xencor compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, Organon & Co. had 2 more articles in the media than Xencor. MarketBeat recorded 6 mentions for Organon & Co. and 4 mentions for Xencor. Xencor's average media sentiment score of 0.65 beat Organon & Co.'s score of 0.32 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 15.24%. Xencor has a consensus target price of $24.50, suggesting a potential upside of 74.01%. Given Xencor's stronger consensus rating and higher possible upside, analysts plainly believe Xencor is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Xencor has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Organon & Co. has a net margin of 3.99% compared to Xencor's net margin of -177.10%. Organon & Co.'s return on equity of 99.95% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Xencor	-177.10%	-28.77%	-20.52%

Organon & Co. has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.16B	0.57	$187M	$0.93	14.46
Xencor	$125.58M	8.31	-$91.92M	-$2.29	N/A

77.4% of Organon & Co. shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Organon & Co. beats Xencor on 10 of the 16 factors compared between the two stocks.

How does Xencor compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Xencor has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.89	-$512.54M	-$2.88	N/A
Xencor	$125.58M	8.31	-$91.92M	-$2.29	N/A

In the previous week, Xencor had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Xencor and 2 mentions for Denali Therapeutics. Xencor's average media sentiment score of 0.65 beat Denali Therapeutics' score of 0.33 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Xencor	-177.10%	-28.77%	-20.52%

Denali Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Xencor has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Denali Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 38.27%. Xencor has a consensus price target of $24.50, suggesting a potential upside of 74.01%. Given Xencor's higher possible upside, analysts clearly believe Xencor is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

92.9% of Denali Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by insiders. Comparatively, 5.1% of Xencor shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Denali Therapeutics beats Xencor on 9 of the 17 factors compared between the two stocks.

How does Xencor compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

89.9% of NewAmsterdam Pharma shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 5.1% of Xencor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Xencor has a net margin of -177.10% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Xencor	-177.10%	-28.77%	-20.52%

NewAmsterdam Pharma has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market. Comparatively, Xencor has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

NewAmsterdam Pharma presently has a consensus target price of $48.60, suggesting a potential upside of 54.78%. Xencor has a consensus target price of $24.50, suggesting a potential upside of 74.01%. Given Xencor's higher probable upside, analysts clearly believe Xencor is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Xencor had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 4 mentions for Xencor and 0 mentions for NewAmsterdam Pharma. Xencor's average media sentiment score of 0.65 beat NewAmsterdam Pharma's score of 0.00 indicating that Xencor is being referred to more favorably in the news media.

Company	Overall Sentiment
NewAmsterdam Pharma	Neutral
Xencor	Positive

Xencor has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	163.14	-$203.82M	-$1.79	N/A
Xencor	$125.58M	8.31	-$91.92M	-$2.29	N/A

Summary

Xencor beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks.

How does Xencor compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Xencor has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Xencor	$125.58M	8.31	-$91.92M	-$2.29	N/A

Viking Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Xencor	-177.10%	-28.77%	-20.52%

76.0% of Viking Therapeutics shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 5.1% of Xencor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Viking Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Xencor has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Viking Therapeutics presently has a consensus target price of $93.60, suggesting a potential upside of 168.89%. Xencor has a consensus target price of $24.50, suggesting a potential upside of 74.01%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Viking Therapeutics had 3 more articles in the media than Xencor. MarketBeat recorded 7 mentions for Viking Therapeutics and 4 mentions for Xencor. Xencor's average media sentiment score of 0.65 beat Viking Therapeutics' score of 0.25 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Viking Therapeutics and Xencor tied by winning 8 of the 16 factors compared between the two stocks.

How does Xencor compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Telix Pharmaceuticals presently has a consensus target price of $21.13, indicating a potential upside of 106.90%. Xencor has a consensus target price of $24.50, indicating a potential upside of 74.01%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Telix Pharmaceuticals has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Telix Pharmaceuticals' return on equity of 0.00% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Xencor	-177.10%	-28.77%	-20.52%

In the previous week, Telix Pharmaceuticals and Telix Pharmaceuticals both had 4 articles in the media. Xencor's average media sentiment score of 0.65 beat Telix Pharmaceuticals' score of 0.44 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market. Comparatively, Xencor has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than Xencor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.31	-$7.12M	N/A	N/A
Xencor	$125.58M	8.31	-$91.92M	-$2.29	N/A

Summary

Telix Pharmaceuticals beats Xencor on 8 of the 11 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XNCR vs. The Competition

Export

Metric	Xencor	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.04B	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-6.15	18.43	24.92	23.98
Price / Sales	8.31	327.41	528.51	109.04
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	1.58	4.11	10.79	6.50
Net Income	-$91.92M	$64.45M	$3.56B	$336.88M
7 Day Performance	15.41%	2.24%	1.67%	-0.22%
1 Month Performance	24.49%	1.04%	0.43%	0.77%
1 Year Performance	67.42%	30.05%	32.84%	31.57%

Xencor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XNCR Xencor	1.8945 of 5 stars	$14.08 +0.5%	$24.50 +74.0%	+64.1%	$1.04B	$125.58M	N/A	280
OGN Organon & Co.	2.6601 of 5 stars	$13.45 +0.0%	$11.40 -15.2%	+37.2%	$3.53B	$6.22B	14.46	10,000	News Coverage
DNLI Denali Therapeutics	3.1542 of 5 stars	$21.70 -2.3%	$34.25 +57.8%	+73.1%	$3.46B	$330.53M	N/A	430	Analyst Forecast
NAMS NewAmsterdam Pharma	2.0301 of 5 stars	$29.32 -4.2%	$48.60 +65.8%	+71.6%	$3.44B	$22.50M	N/A	4
VKTX Viking Therapeutics	2.5438 of 5 stars	$29.07 -1.9%	$93.60 +222.0%	+24.5%	$3.38B	N/A	N/A	20	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XNCR) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xencor (XNCR) Competitors

XNCR vs. OGN, DNLI, NAMS, VKTX, and TLX

How does Xencor compare to Organon & Co.?

Summary

How does Xencor compare to Denali Therapeutics?

Summary

How does Xencor compare to NewAmsterdam Pharma?

Summary

How does Xencor compare to Viking Therapeutics?

Summary

How does Xencor compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xencor (XNCR) Competitors

XNCR vs. OGN, DNLI, NAMS, VKTX, and TLX

How does Xencor compare to Organon & Co.?

Does the media prefer OGN or XNCR?

Do analysts prefer OGN or XNCR?

Which has more volatility & risk, OGN or XNCR?

Is OGN or XNCR more profitable?

Which has better valuation and earnings, OGN or XNCR?

Do insiders and institutionals have more ownership in OGN or XNCR?

Summary

How does Xencor compare to Denali Therapeutics?

Which has higher earnings & valuation, DNLI or XNCR?

Does the media prefer DNLI or XNCR?

Is DNLI or XNCR more profitable?

Which has more risk and volatility, DNLI or XNCR?

Do analysts prefer DNLI or XNCR?

Do institutionals & insiders have more ownership in DNLI or XNCR?

Summary

How does Xencor compare to NewAmsterdam Pharma?

Do insiders & institutionals hold more shares of NAMS or XNCR?

Is NAMS or XNCR more profitable?

Which has more volatility & risk, NAMS or XNCR?

Do analysts recommend NAMS or XNCR?

Does the media prefer NAMS or XNCR?

Which has higher earnings & valuation, NAMS or XNCR?

Summary

How does Xencor compare to Viking Therapeutics?

Which has higher earnings & valuation, VKTX or XNCR?

Is VKTX or XNCR more profitable?

Do insiders & institutionals hold more shares of VKTX or XNCR?

Which has more volatility & risk, VKTX or XNCR?

Do analysts recommend VKTX or XNCR?

Does the media prefer VKTX or XNCR?

Summary

How does Xencor compare to Telix Pharmaceuticals?

Do analysts recommend TLX or XNCR?

Is TLX or XNCR more profitable?

Does the media prefer TLX or XNCR?

Which has more risk & volatility, TLX or XNCR?

Which has stronger earnings and valuation, TLX or XNCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools